NeuroLife® is a non-invasive neurotechnology company advancing a scalable, IP-rich neurotechnology platform designed to restore functional recovery for millions affected by stroke and spinal cord injury through intelligent, signal-driven therapy.
Someone in the United States has a stroke *1
Survivors experience hemiparesis or weakness on one side of the body *2
Spinal cord injuries per year
The NeuroLife platform bridges the gap between neural intent and physical action through a high-resolution, non-invasive interface.
How it Works
Proprietary EMG arrays capture detailed neuromuscular signals that reflect specific movement intent.
Advanced algorithms translate muscle activation patterns into actionable data in real-time.
A closed-loop system provides personalized stimulation to support functional hand and arm use during a patient's physical therapy rehabilitation.
Rapid calibration and a wearable sleeve format ensure the system fits seamlessly into existing clinical workflows.
— SCI study participant
Jon Snyder is Chief Executive Officer of NeuroLife, a development stage neuromodulation company focused on restoring grasp for patients living with spinal cord injury and stroke.
Justin Sanchez, PhD is a Battelle Technical Fellow. As a noted expert in biotechnology, he creates strategic vision to guide Battelle’s life sciences and biotechnology businesses.
Matthew McFarland, PhD is Vice President of Technology Strategy and Partnerships at Battelle, where he leads efforts to translate advanced science and engineering into commercial ventures, strategic partnerships, and real-world impact.
The Battelle Neurotechnology R&D team brings together deep expertise in neuroscience, engineering, and signal processing to develop non-invasive technologies that interpret neuromuscular signals and respond in real time.
